FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2994582016> ?p ?o ?g. }

• W2994582016 abstract "Currently there is a great interest towards recombinant factor VIII (rFVIII) products that have technological solutions to prolong their half-life and to reduce the risk of alloantibodies against FVIII (inhibitors). At the present the Italian Health Care System offers a wide range of rFVIII concentrates belonging to the first generation as well as to the third generation, some of which with peculiar pharmacodinamic and pharmacocinetic (PK) prophiles, up to an extended half-life (EHL) product. The first generation full-length rFVIII (FL-rFVIII) octocog alfa (Recombinate® Baxter/BIOVIIIx), although is the oldiest rFVIII product, has some features that make it quite current. To the third generation products belong two modified rFVIII octocog alfa molecules (Advate®-Shire and Kovaltry®-Bayer), followed by B domain deleted rFVIII (BDD-rFVIII) moroctocog alfa (ReFacto®-Pfizer), B domain truncated (BDT-rFVIII) turoctocog alfa (NovoEight®, Novo Nordisk), BDD-rFVIII simoctocog alfa (Nuwiq®, Kedrion), single-chain BDT-rVIII lonoctocog alfa (Afstyla®- CSL Behring) and BDD-rFVIIIFc efmoroctocog alfa (Elocta®, Sobi-Biogen). Turoctocog alfa, simoctocog alfa and lonoctocog alfa may be considered innovative products. Their high affinity to von Willebrand factor (vWF) helps to reduce renal clearance and to prolong someway half-life. Efmoroctocog alfa, a first-in-class rFVIII-Fc fusion protein (rFVIIIFc) belongs to EHL products with a half life 1.5 times longer than that of conventional plasma-derived FVIII (pd-rFVIII) and rFVIII products. All this concentrates have been shown their efficacy, safety and immunogenecity in clinical studies both on previous treated patients (PTPs) and on previous untreated ones (PUPs).This review considers the commercially available rFVIII products in Italy indicated for treatment of patients with severe hemophilia A (HA), highlighting their PK characteristics, immunogenicity and benefits from a clinical point of view." @default.
• W2994582016 created "2019-12-13" @default.
• W2994582016 creator A5001007530 @default.
• W2994582016 creator A5006539823 @default.
• W2994582016 creator A5026676198 @default.
• W2994582016 creator A5028743501 @default.
• W2994582016 creator A5039120727 @default.
• W2994582016 creator A5054597075 @default.
• W2994582016 creator A5065229532 @default.
• W2994582016 creator A5085841362 @default.
• W2994582016 date "2019-12-03" @default.
• W2994582016 modified "2023-10-18" @default.
• W2994582016 title "Status of Recombinant Factor VIII Concentrate Treatment for Hemophilia A in Italy: Characteristics and Clinical Benefits" @default.
• W2994582016 cites W1525469616 @default.
• W2994582016 cites W1527938269 @default.
• W2994582016 cites W1540151595 @default.
• W2994582016 cites W1586003096 @default.
• W2994582016 cites W1684292764 @default.
• W2994582016 cites W1712731942 @default.
• W2994582016 cites W1754890660 @default.
• W2994582016 cites W1756091829 @default.
• W2994582016 cites W1936160456 @default.
• W2994582016 cites W1941313698 @default.
• W2994582016 cites W1963967196 @default.
• W2994582016 cites W1973955551 @default.
• W2994582016 cites W1974965024 @default.
• W2994582016 cites W1979242063 @default.
• W2994582016 cites W1986908979 @default.
• W2994582016 cites W1987252130 @default.
• W2994582016 cites W1991223023 @default.
• W2994582016 cites W1997223335 @default.
• W2994582016 cites W2000958165 @default.
• W2994582016 cites W2005644068 @default.
• W2994582016 cites W2005662779 @default.
• W2994582016 cites W202913011 @default.
• W2994582016 cites W2033176757 @default.
• W2994582016 cites W2037201482 @default.
• W2994582016 cites W2037452739 @default.
• W2994582016 cites W2062520517 @default.
• W2994582016 cites W2066646645 @default.
• W2994582016 cites W2067732954 @default.
• W2994582016 cites W2072339301 @default.
• W2994582016 cites W2073193633 @default.
• W2994582016 cites W2080205609 @default.
• W2994582016 cites W2085306050 @default.
• W2994582016 cites W2091207267 @default.
• W2994582016 cites W2104523338 @default.
• W2994582016 cites W2106536550 @default.
• W2994582016 cites W2126744194 @default.
• W2994582016 cites W2147887043 @default.
• W2994582016 cites W2157479261 @default.
• W2994582016 cites W2167801052 @default.
• W2994582016 cites W2168608087 @default.
• W2994582016 cites W2195470521 @default.
• W2994582016 cites W2237179746 @default.
• W2994582016 cites W2289169982 @default.
• W2994582016 cites W2401865216 @default.
• W2994582016 cites W2413214319 @default.
• W2994582016 cites W2420811477 @default.
• W2994582016 cites W2471135389 @default.
• W2994582016 cites W2471681322 @default.
• W2994582016 cites W2472001395 @default.
• W2994582016 cites W2592750169 @default.
• W2994582016 cites W2607714781 @default.
• W2994582016 cites W2748331328 @default.
• W2994582016 cites W2809916805 @default.
• W2994582016 cites W2884785622 @default.
• W2994582016 cites W2899796162 @default.
• W2994582016 cites W2920241918 @default.
• W2994582016 cites W2954658878 @default.
• W2994582016 cites W4323282389 @default.
• W2994582016 cites W72264405 @default.
• W2994582016 cites W2474616625 @default.
• W2994582016 doi "https://doi.org/10.3389/fmed.2019.00261" @default.
• W2994582016 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6901793" @default.
• W2994582016 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31850352" @default.
• W2994582016 hasPublicationYear "2019" @default.
• W2994582016 type Work @default.
• W2994582016 sameAs 2994582016 @default.
• W2994582016 citedByCount "22" @default.
• W2994582016 countsByYear W29945820162020 @default.
• W2994582016 countsByYear W29945820162021 @default.
• W2994582016 countsByYear W29945820162022 @default.
• W2994582016 countsByYear W29945820162023 @default.
• W2994582016 crossrefType "journal-article" @default.
• W2994582016 hasAuthorship W2994582016A5001007530 @default.
• W2994582016 hasAuthorship W2994582016A5006539823 @default.
• W2994582016 hasAuthorship W2994582016A5026676198 @default.
• W2994582016 hasAuthorship W2994582016A5028743501 @default.
• W2994582016 hasAuthorship W2994582016A5039120727 @default.
• W2994582016 hasAuthorship W2994582016A5054597075 @default.
• W2994582016 hasAuthorship W2994582016A5065229532 @default.
• W2994582016 hasAuthorship W2994582016A5085841362 @default.
• W2994582016 hasBestOaLocation W29945820161 @default.
• W2994582016 hasConcept C104317684 @default.
• W2994582016 hasConcept C126322002 @default.
• W2994582016 hasConcept C166957645 @default.
• W2994582016 hasConcept C185592680 @default.
• W2994582016 hasConcept C205649164 @default.
• W2994582016 hasConcept C2776863037 @default.

• next